Cellosaurus logo
expasy logo

Cellosaurus M249 R4 (CVCL_EI93)

[Text version]
Cell line name M249 R4
Synonyms M249-AR4; M249AR4
Accession CVCL_EI93
Resource Identification Initiative To cite this cell line use: M249 R4 (RRID:CVCL_EI93)
Comments Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
Sequence variations
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_D755 (M249)
Sex of cell Sex unspecified
Age at sampling Age unspecified
Category Cancer cell line

PubMed=21107323; DOI=10.1038/nature09626
Nazarian R., Shi H.-B., Wang Q., Kong X.-J., Koya R.C., Lee H., Chen Z.-G., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S.F., McArthur G.A., Sosman J.A., Ribas A., Lo R.S.
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature 468:973-977(2010)

PubMed=22194965; DOI=10.1371/journal.pone.0028973
Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R., Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S., Ribas A.
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PLoS ONE 6:E28973-E28973(2011)

PubMed=25645078; DOI=10.1186/s12943-015-0293-5
Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A., Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B., Graeber T.G., Ribas A.
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Mol. Cancer 14:27.1-27.12(2015)

Cell line databases/resources cancercelllines; CVCL_EI93
Encyclopedic resources Wikidata; Q54903563
Polymorphism and mutation databases Cosmic; 1545619
Entry history
Entry creation26-Sep-2016
Last entry update05-Oct-2023
Version number11